Literature DB >> 3305786

Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients.

D A Paul, L A Falk, H A Kessler, R M Chase, B Blaauw, D S Chudwin, A L Landay.   

Abstract

An enzyme immunoassay (EIA) has been developed which detects antigen(s) (Ag) of the human immunodeficiency virus (HIV) in the serum of patients with the acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), and patients at high risk for HIV infection. The test has a sensitivity of approximately 50 pg/ml of HIV protein. The specificity of the assay was determined with various virus infected cell lines, normal human sera/plasma, and serum from patients not known to be at risk for HIV infection. No false-positive HIV-Ag results were seen. Sera from 69% of patients with AIDS were positive for HIV-Ag as were 46% of patients with ARC and 19% of asymptomatic, HIV-antibody-positive individuals. There were significant associations between the stage of HIV infection--ie, AIDS vs ARC vs asymptomatic--and the detection of HIV-Ag in serum (p less than 0.0001) and the lack of detection of antibody to HIV core Ag (p less than 0.0001). HIV-Ag was also found in the serum of two asymptomatic antibody-negative individuals who were at high risk for AIDS and who later developed HIV antibody. The presence of HIV-Ag in sera was confirmed by an inhibition procedure. Thus, HIV-Ag can be detected in the serum of infected individuals prior to antibody production and correlates with the clinical stage of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3305786     DOI: 10.1002/jmv.1890220408

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  31 in total

1.  Improved detection of HIV p24 antigen in serum after acid pretreatment.

Authors:  M A Rodríguez-Iglesias; J R Alvarez; A Vergara; M S Garcia-Valdivia; I Jesús; J Mira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

2.  Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction.

Authors:  S Menzo; P Bagnarelli; M Giacca; A Manzin; P E Varaldo; M Clementi
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

Review 3.  Clinical, virological and immunological features of primary HIV-1 infection.

Authors:  M D de Jong; H J Hulsebosch; J M Lange
Journal:  Genitourin Med       Date:  1991-10

4.  Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.

Authors:  D J Kempf; K C Marsh; D A Paul; M F Knigge; D W Norbeck; W E Kohlbrenner; L Codacovi; S Vasavanonda; P Bryant; X C Wang
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  H Revets; D Marissens; S de Wit; P Lacor; N Clumeck; S Lauwers; G Zissis
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

6.  Antigen detection in primary HIV infection.

Authors:  M von Sydow; H Gaines; A Sönnerborg; M Forsgren; P O Pehrson; O Strannegård
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-23

7.  The impaired number of circulating granulocyte/macrophage progenitors (CFU-GM) in human immunodeficiency virus-type 1 infected subjects correlates with an active HIV-1 replication.

Authors:  M C Re; G Zauli; G Furlini; S Ranieri; P Monari; E Ramazzotti; M La Placa
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

8.  Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay.

Authors:  M B Vasudevachari; N P Salzman; D R Woll; C Mast; K W Uffelman; G Toedter; D Hoefheinz; J A Metcalf; H C Lane
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

9.  Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients.

Authors:  A I Hussain; V Shanmugam; W M Switzer; S X Tsang; A Fadly; D Thea; R Helfand; W J Bellini; T M Folks; W Heneine
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

10.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.

Authors:  P Simmonds; P Balfe; J F Peutherer; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.